The albumin–bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag179 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 07.05.2026. Verfasst von Ming-Yang Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan. Hauptthemen laut MEDLINE: Bilirubin, Biliary Tract Neoplasms, Antibodies, Monoclonal, Serum Albumin. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Foundation.
Abstract (Originalsprache)
Background
The albumin–bilirubin (ALBI) score objectively reflects hepatic functional reserve and is widely used as a prognostic biomarker in hepatocellular carcinoma. However, its prognostic value in patients with biliary tract carcinoma (BTC) treated with durvalumab plus gemcitabine–cisplatin (GCD) remains unclear. Material and Methods We retrospectively analyzed 172 patients with unresectable or metastatic BTC who received first-line GCD between 2021 and 2025. Baseline ALBI scores were calculated and patients were stratified into cohort-specific tertiles (Q1-Q3). Overall survival (OS) was estimated using Kaplan–Meier method and Cox regression hazards models. Predictive performance for OS was compared between ALBI and the Eastern Cooperative Oncology Group performance status (ECOG PS) using time-dependent area under the receiver operating characteristic curves (AUC) analysis.
Results
The median OS was 13.8 months (95% CI, 9.9-17.7). Survival differed significantly across ALBI tertiles: median OS was 24.0 months (95% CI, 10.3-37.8) for Q1, 14.4 months (95% CI, 9.2-19.6) for Q2, and 5.9 months (95% CI, 2.5-9.2) for Q3 (P < .001). In multivariate analysis, ALBI remained an independent prognostic factor for OS (Q3 vs Q1, adjusted hazard ratio 2.16; 95% CI, 1.16-4.04; P = .016). The ALBI score demonstrated improved prognostic discrimination (AUC 0.714 at 6 months; 0.656 at 12 months) compared with ECOG PS (AUC 0.591 and 0.551, respectively). Tumor response rates were similar across tertiles, but higher ALBI scores were associated with an increased incidence of grade ≥3 toxicities.
Conclusion
The pretreatment ALBI score is a simple, objective, and independent prognostic biomarker for patients with advanced BTC receiving durvalumab-based immunochemotherapy. Incorporating ALBI into baseline assessment may help identify high-risk patients who warrant closer monitoring or individualized therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
- Department of Hematology and Oncology, Chang Gung Memorial Hospital at Keelung, Keelung 204, Taiwan.
- Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan.
- Department of Hematology and Oncology, New Taipei Municipal TuCheng Hospital, New Taipei City 236, Taiwan.
ORCID-Profile: Wen-Chi Chou
Förderung
- Chang Gung Memorial Foundation
Zitieren
APA
Chen, M. Y., Kou, H. W., Wu, T. H., Lan, C. C., Chen, J. S., Hsieh, C. H., Hung, Y. S., & Chou, W. C. (2026). The albumin–bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag179
Vancouver
Chen MY, Kou HW, Wu TH, Lan CC, Chen JS, Hsieh CH, et al. The albumin–bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag179
BibTeX
@article{Chen2026,
author = {Chen, Ming-Yang and Kou, Hao-Wei and Wu, Tsung-Han and Lan, Chi-Chen and Chen, Jen-Shi and Hsieh, Chia-Hsun and Hung, Yu-Shin and Chou, Wen-Chi},
title = {The albumin–bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag179}
}
EUVIMED